microRNA therapy in tendon disease

One in ten people will develop tendinopathy—a painful, degenerative tendon condition—yet physiotherapy, the best available treatment, helps only half of them. Causeway Therapeutics has identified the molecular mechanism that turns a damaged tendon into a chronically diseased one. Based on that discovery, the company developed TenoMiR, a microRNA therapy that directly targets the core disease process rather than just managing symptoms. In preclinical tests, TenoMiR restored both the structure and function of damaged tendons. If this therapy succeeds in human trials, it would become the first drug treatment for tendinopathy, filling a gap that has left millions of patients with no effective medical option. The grant funds the development of TenoMiR through an early-stage clinical trial in humans. A working therapy could reduce the need for prolonged physiotherapy, shorten recovery times, and prevent the progression to tendon rupture—a common outcome that often requires surgery and months of rehabilitation. For a condition that affects roughly 10 percent of the population, even a modest improvement in treatment success would shift the standard of care.